Alkermes News

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Boston CEO Conference to Feature CEOs of Alkermes plc , Alnylam Pharmaceuticals , Ariad Pharmaceuticals, Inc.

The firm currently has a "neutral" rating on the stock. The analysts wrote, "ALKS saw $46 mn in revenues from JNJ's Consta and Sustenna, slightly ahead of our $44 mn.

Apple Inc. : Jim Cramer ranked this stock a Buy . The stock closed at $570.52, its 52-week high is $644.00, and its 52-week low is $310.50. Alkermes, Inc.

NEW YORK -- It's easy to focus on what's wrong with the markets, Jim Cramer told his "Mad Money" TV show viewers Thursday.

The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money.

ALKS -3.3% WCRX +16.07% BSX +0.97% MRK +2.03% UNH -3.11% FRX -0.26% RHHBY +0.46% PFE -0.65% Edward Owens bought only one new stock and added to seven others in the first quarter of 2012.